Latest Options News

Taruga Minerals has entered a 12-month option to acquire two advanced gold and copper projects in Papua New Guinea, backed by a $1.5 million capital raise to fund exploration and resource development.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Li-FT Power Ltd. has agreed to acquire Winsome Resources Limited and a controlling interest in the Galinée property, aiming to create a leading hard rock lithium developer in Canada with enhanced resource scale and market presence.

Wellard Limited's shares have been suspended from trading on the ASX as the company moves toward official delisting, marking a significant shift for investors and the livestock export sector.

Boab Metals has successfully raised A$60 million through a two-tranche placement and launched a Share Purchase Plan to complete funding for its Sorby Hills Lead-Silver Project in Western Australia.

Pure Resources Limited has raised $1.7 million through a share placement and option issuance to advance its Garnet Hills graphite project, highlighting promising jumbo flake graphite findings.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Future Metals NL has completed strategic planning that enhances its flagship Panton PGM Project’s value, driven by a 35% rise in platinum group metal prices and expanded exploration programs. The company is also advancing infrastructure options and strengthening its management team to accelerate development.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.